SEATTLE -- Corixa Corporation, a developer of immunotherapeutics, announced that the Committee For Medicinal Products for Human Use (CHMP) the scientific body of the European Medicines Evaluation Agency (EMEA), has issued a positive opinion for Fendrix(R), GlaxoSmithKline Biologicals' (GSK Bio) vaccine for the prevention of hepatitis B in specific high-risk groups. Fendrix is a novel vaccine, containing Corixa's MPL(R) adjuvant, which is designed to help prevent infection from hepatitis B in specific high-risk groups such as pre-haemodialysis and haemodialysis patients. This positive opinion represents an important step in the continuing commercial development of Corixa's MPL adjuvant, which is included in several late stage GSK Bio specific vaccine product candidates.
The opinions of the CHMP generally serve as the basis for European Commission approvals. European Commission approvals are typically issued three months after the CHMP opinions are issued. However, Fendrix is not yet approved.
"We are pleased to announce today's progress toward commercialization of our MPL adjuvant," said Steven Gillis, PhD, chairman and chief executive officer of Corixa. "Given that MPL adjuvant is a component of several additional GSK Bio vaccines now in late stage clinical trials, we look forward to the growth of our adjuvant business and its potential contribution to Corixa's future product sales and royalty income."
Adjuvants are formulated compounds or additives that help to boost the body's immune response when combined with vaccine antigens. In addition to GSK Biologicals' Fendrix vaccine, MPL is present in a number of GSK Bio vaccines now in late stage clinical development, including a vaccine under investigation for the prevention of cervical cancer, and another vaccine under investigation for the prevention of genital herpes.
Source: Corixa Corp.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.